Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Mild Cognitive Impairment Companies

Mild Cognitive Impairment (MCI) is a condition characterized by noticeable cognitive decline that is greater than expected for an individual's age but not severe enough to interfere significantly with daily life. Various pharmaceutical and healthcare companies may be involved in research, drug development, and initiatives related to cognitive health, including MCI.

Mild Cognitive Impairment Key Companies

Latest Mild Cognitive Impairment Companies Update

Eli Lilly receives Fast Track designation for donanemab in MCI: In December 2023, Lilly received FDA Fast Track designation for donanemab, an anti-amyloid antibody, for the treatment of early Alzheimer's disease and MCI due to Alzheimer's pathology. This signifies a potential acceleration in the drug's approval process.

Biogen announces plans for Phase 3 trials of aducanumab in MCI Despite aducanumab's controversial approval for Alzheimer's disease, Biogen is planning Phase 3 trials to assess its efficacy in MCI prevention. This could potentially expand the drug's reach earlier in the disease progression.

TauRx Therapeutics reports positive Phase 2a results for TauRX301 in progressive supranuclear palsy (PSP) While not directly targeting MCI, TauRx Therapeutics' positive Phase 2a results for TauRX301 offer hope for developing similar Tau-targeting therapies for MCI and other neurodegenerative diseases.

List of Mild Cognitive Impairment Key Companies in The Market

Pfizer Inc. (US)

Hoffman La Roche Ltd (Switzerland)

Novartis AG (Switzerland)

Accord UK Ltd (UK)

Reddy’s laboratories Ltd (India)

Hikma Pharmaceuticals PLC (UK)

Sun Pharmaceuticals ltd (India)

Johnson & Johnson Services, Inc. (US)

Teva Pharmaceutical Industries Ltd., (Israel)

Takeda Pharmaceutical Company Limited (US)

Mild Cognitive Impairment Market Highlights:

Mild Cognitive Impairment Market Size

Mild Cognitive Impairment Market Trends

Mild Cognitive Impairment Market Analysis

Mild Cognitive Impairment Market Share

Mild Cognitive Impairment Market Highlights:

Mild Cognitive Impairment Market Trends

Mild Cognitive Impairment Market Analysis

Mild Cognitive Impairment Market Share

Mild Cognitive Impairment Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.